Anonymous
Guest
Anonymous
Guest
hahahahaha horrible business development people at Allergan
When Pyott took over as CEO and President of Allergan in 1998 the stock was trading at $8 per share with annual sales of $716 million. Today Allergan nets over $5.3 billion in product sales and the stock is $95 per share.
Let's see, Pyott versus OP......................hhhhhhmmmmmmmmmmmmm. I will go with Pyott.
The measure of a great leader is not only about stock price. I'll give Pyott his due on the stock, but the company has been a bad place to work for a long time, and he knows it but won't take the steps to improve the situation.
The measure of a great leader is not only about stock price. I'll give Pyott his due on the stock, but the company has been a bad place to work for a long time, and he knows it but won't take the steps to improve the situation.
This company treats high performing tenured employees terrible and pays a great deal to bring in pharm benefit manager levels from other companies as director levels here just to fill seats. No one wants to work here anymore. Each position is doing the work many. That is why stock is high. Furniture in offices is an embarrassment. 3% raises for exceeding expectations. Are you kidding me? Tightest company I've worked for in my 20 years in the industry.
Nothing bad to say about Pyott, never even really the guy... only interaction is during his stage shows. The corporate culture and how they treat people though, pretty lame.